Garfield Alastair, Chief Scientific Officer at Rhythm Pharmaceuticals ($RYTM), made two open market sales of company shares over the past year, totaling about $85,500. His latest sale occurred on July 2, 2025. These transactions rank 9,790th among 11,678 insiders in our database by sale value, well below the average of $8.6 million across 6.4 transactions per insider. He recorded no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 11, 2026 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | A | Restricted Stock Units | 16650 | $0.00 | 16,650.0000 | 64,984,361 | 9999.99% | 0.03% |
| Feb. 11, 2026 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | A | Stock Options (Right to Buy) | 25000 | $0.00 | 25,000.0000 | 64,984,361 | 9999.99% | 0.04% |
| Feb. 1, 2026 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | M | Restricted Stock Units | 6663 | $0.00 | 19,987.0000 | 64,984,361 | 25.00% | 0.01% |
| Feb. 1, 2026 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | F | Common Stock | 2026 | $108.99 | 7,763.0000 | 64,984,361 | 20.70% | 0.00% |
| Feb. 1, 2026 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | M | Common Stock | 6663 | $0.00 | 9,789.0000 | 64,984,361 | 213.15% | 0.01% |
| July 1, 2025 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | M | Common Stock | 4445 | $0.00 | 4,445.0000 | 63,684,359 | 9999.99% | 0.01% |
| July 2, 2025 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | S | Common Stock | 1313 | $64.81 | 3,132.0000 | 63,684,359 | 29.54% | 0.00% |
| July 2, 2025 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | S | Common Stock | 6 | $64.60 | 3,126.0000 | 63,684,359 | 0.19% | 0.00% |
| July 1, 2025 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | M | Restricted Stock Units | 4445 | $0.00 | 13,333.0000 | 63,684,359 | 25.00% | 0.01% |
| Feb. 14, 2025 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | A | Stock Options (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 60,995,204 | 9999.99% | 0.07% |
| Feb. 14, 2025 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | A | Restricted Stock Units | 26650 | $0.00 | 26,650.0000 | 60,995,204 | 9999.99% | 0.04% |
| July 8, 2024 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | A | Restricted Stock Units | 17778 | $0.00 | 17,778.0000 | 61,011,824 | 9999.99% | 0.03% |
| July 8, 2024 | RHYTHM PHARMACEUTICALS, INC. | $RYTM | Garfield Alastair | Chief Scientific Officer | A | Stock Option (right to buy) | 53333 | $0.00 | 53,333.0000 | 61,011,824 | 9999.99% | 0.09% |